[Results of a phase I clinical trial of "theraphthal + ascorbic acid" catalytic system].
Phase-I clinical studies of teraphtal and a "teraphtal + ascorbic acid" catalytic system have been completed. The dose-limiting toxicity and maximum tolerable dose were not reached even at the end of maximal dose trials. No side-effects characteristic of antitumor cytostatic drugs were registered. The gravest side-effect ever recorded was a collapse which could not be linked to teraphtal dosage and was probably caused by hypersensitivity to the drug. The drug was recommended for phase II trials.
Garin
A M
AM
Gorbunova
V A
VA
Gershanovich
M L
ML
Manziuk
L V
LV
Borodkina
A G
AG
Breder
V V
VV
Karmanovskaia
O B
OB
Zubrikhina
G N
GN
Madzhuga
A V
AV
Zimakova
N I
NI
Trapeznikov
N N
NN
D000310:Adrenal Gland Neoplasms / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D003110:Colonic Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D012509:Sarcoma / Q000188:drug therapy; D012878:Skin Neoplasms / Q000188:drug therapy; D012983:Soft Tissue Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D007211:Indoles; C403768:theraphthal